Highlights•The incidence of HCC will continue to rise.•HCC is curable at an early
stage.•New locoregional treatments such as radioembolisation are showing impressive …

Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Background Tumor proliferation is frequently accompanied by aberrant enzyme production.
We aim to investigate the potential predictive value of both plasma alkaline phosphatase …

Abstract Background Body composition parameters (BCPs) are associated with mortality in
patients with hepatocellular carcinoma (HCC). Our purpose was to develop a practical …

Background & Aims Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …

Abstract Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become
the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC) …

Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment
for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the …

Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in
Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma …

Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and is
considered a major global health problem as one of the leading causes of cancer-related …

Conclusions: RECIST 1.1 and mRECIST criteria predict overall survival with more
responders identified by mRECIST and the appearance of new extrahepatic lesion or …